 BridgeBio Pharma Inc NASDAQ: BBIO has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i LGMD2i, a group of conditions that cause weakness and wasting of the muscles in the arms and legs. The Company plans to engage with. 